(Q56864518)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

0 references

1 reference

non-small-cell lung carcinoma

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Enzo Alessio

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Gianni Sava

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

9

Jos H Beijnen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

10

Jan H M Schellens

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Suzanne Leijen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Paul Baas

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Dick Pluim

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Matthijs Tibben

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Sjaak A Burgers

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

25 October 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

21 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

201-214

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10637-014-0179-1

21 February 2020

exact match

0 references

cites work

Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine

1 reference

12 December 2020

A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.

1 reference

12 December 2020

Blood levels of ruthenium following repeated treatments with the antimetastatic compound NAMI-A in healthy beagle dogs

1 reference

12 December 2020

Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties

1 reference

12 December 2020

Molecular interactions of ruthenium complexes in isolated mammalian nuclei and cytotoxicity on V79 cells in culture

1 reference

12 December 2020

Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry

1 reference

12 December 2020

Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.

1 reference

12 December 2020

Drug control of solid tumour metastases: a critical view.

1 reference

12 December 2020

NAMI-A inhibits the PMA-induced ODC gene expression in ECV304 cells: involvement of PKC/Raf/Mek/ERK signalling pathway.

1 reference

12 December 2020

A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin

1 reference

12 December 2020

Medicinal applications of heavy-metal compounds

1 reference

12 December 2020

Effects of hypoxia and transferrin on toxicity and DNA binding of ruthenium antitumor agents in hela cells

1 reference

12 December 2020

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice.

1 reference

12 December 2020

Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.

1 reference

12 December 2020

Inhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A.

1 reference

12 December 2020

New cisplatin analogues in development. A review

1 reference

12 December 2020

Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition

1 reference

12 December 2020

Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex

1 reference

12 December 2020

Ruthenium-based chemotherapeutics: are they ready for prime time?

1 reference

12 December 2020

Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes

1 reference

12 December 2020

Selective antimetastatic drugs (review).

1 reference

12 December 2020

Ruthenium complexes as anticancer agents

1 reference

12 December 2020

Optimal two-stage designs for phase II clinical trials

1 reference

12 December 2020

DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.

1 reference

12 December 2020

Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry

1 reference

12 December 2020

Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers.

1 reference

12 December 2020

Design and analysis of phase I clinical trials

1 reference

12 December 2020

TGFbeta1 regulation and collagen-release-independent connective tissue re-modelling by the ruthenium complex NAMI-A in solid tumours

1 reference

12 December 2020

Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates

1 reference

12 December 2020

Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation

1 reference

12 December 2020

Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines

1 reference

12 December 2020

New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA.

1 reference

12 December 2020

A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.

1 reference

12 December 2020

Reduction and subsequent binding of ruthenium ions catalyzed by subcellular components

1 reference

12 December 2020

Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells.

1 reference

12 December 2020

The anti-metastatic agent imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway

1 reference

12 December 2020

Features and full reversibility of the renal toxicity of the ruthenium-based drug NAMI-A in mice

1 reference

12 December 2020

Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.

1 reference

12 December 2020

Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A.

1 reference

12 December 2020

Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A

1 reference

12 December 2020

Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches

1 reference

12 December 2020

Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.

1 reference

12 December 2020

Cisplatin and derived anticancer drugs: mechanism and current status of DNA binding.

1 reference

12 December 2020

Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs.

1 reference

12 December 2020

Effects of the Ru(III) complexes [mer-RuCl3(DMSO)2Im]degrees and Na[trans-RuCl4(DMSO)Im] on solid mouse tumors

1 reference

12 December 2020

Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors

1 reference

12 December 2020

Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A.

1 reference

12 December 2020

Non platinum metal complexes as anti-cancer drugs

1 reference

12 December 2020

Free exchange across cells, and echistatin-sensitive membrane target for the metastasis inhibitor NAMI-A (imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate) on KB tumor cells.

1 reference

12 December 2020

Non-platinum chemotherapeutic metallopharmaceuticals

1 reference

12 December 2020

Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.

1 reference

12 December 2020

Binding of Antitumor Ruthenium(III) Complexes to Plasma Proteins

1 reference

12 December 2020

Intratumoral NAMI-A treatment triggers metastasis reduction, which correlates to CD44 regulation and tumor infiltrating lymphocyte recruitment

1 reference

12 December 2020

Ruthenium complexes can target determinants of tumour malignancy

1 reference

12 December 2020

In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.

1 reference

12 December 2020

Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A.

1 reference

12 December 2020

Recent developments in the field of anticancer platinum complexes

1 reference

12 December 2020

Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A.

1 reference

12 December 2020

Ruthenium anticancer drugs

1 reference

12 December 2020

10.1007/S10637-014-0179-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25344453%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference